Since Mounjaro became available on the NHS in 2025, it has been one of the most searched questions in the UK. The honest answer is: yes, it is available, but access is tightly restricted, and the vast majority of people who would benefit from it do not currently qualify. Here is a clear breakdown of where things stand, who qualifies, and what your options are if you do not meet the criteria.

The NHS rollout timeline

Mounjaro received NICE approval for weight management in England in February 2024. Rollout happened in two stages.

March 2025: available through specialist NHS weight management services (Tier 3), typically via GP referral with a waiting list.

June 23, 2025: NHS England launched primary care prescribing, meaning GPs in England could begin prescribing Mounjaro directly.

Important caveat: implementation has varied significantly by Integrated Care Board (ICB). A BMJ investigation in January 2026 found one in five local areas still lacked a functional NHS pathway for Mounjaro. If your GP is not yet set up to prescribe, you will need to wait until they are.

Who currently qualifies for NHS Mounjaro?

The NHS is using a phased 12-year approach to reach an estimated 3.4 million eligible patients. Only those with the highest clinical need are being prioritised first.

Current eligibility (Cohort 1, from June 2025), must meet ALL of:

  • Aged 18 or over
  • BMI of 40 kg/m² or above
  • At least 4 of the following 5 weight-related conditions, formally diagnosed: type 2 diabetes, hypertension requiring medication, dyslipidaemia, cardiovascular disease, obstructive sleep apnoea
  • Agreement to participate in a structured lifestyle support programme

Phased expansion from June 2026:

Expanding to include patients with BMI 35 to 39.9 with 4 conditions, and BMI 40 with 3 conditions.

Having type 2 diabetes and a BMI of 35 is not sufficient on its own for Cohort 1. Less than 1% of obese adults in the UK currently qualify under the initial rollout.

How does the NHS identify eligible patients?

GP surgeries are proactively identifying eligible patients through medical records and contacting them directly when the prescribing service is ready. Patients should not self-refer. This overwhelms practices and delays the rollout.

If you believe you meet the criteria and have not been contacted, you can ask your GP whether their surgery is participating and whether you appear to be eligible.

NHS Mounjaro vs private Mounjaro

Private eligibility is significantly more accessible, under the MHRA marketing authorisation: BMI ≥30, or BMI ≥27 with at least one weight-related health condition.

Patients who don't meet NHS Cohort 1 criteria can access Mounjaro privately following a clinical consultation. Clinical safety standards, contraindication screening, monitoring, are the same. The medication itself is identical: Mounjaro (tirzepatide) by Eli Lilly, same doses, same KwikPen.

Can I switch from private to NHS?

Not automatically. NHS eligibility is assessed at time of referral based on current BMI and comorbidities, not when private treatment began. If you meet Cohort 1 criteria, discuss with your GP. Your surgery must be set up to prescribe and there may be a wait.

When to see your pharmacist or doctor
  • You believe you meet NHS Cohort 1 criteria but have not been contacted by your GP
  • You are interested in starting treatment privately while waiting for NHS access
  • Before stopping any current private treatment
  • Questions about how NHS access would affect your current treatment plan
References
NHS England. Weight management injections. england.nhs.uk.
NICE Technology Appraisal TA1026 (2024).
NHS England Interim Commissioning Guidance: Tirzepatide for weight management in primary care (2025).
MHRA Summary of Product Characteristics: Mounjaro (tirzepatide), 2024.

Reviewed by Jimah Alsaai MPharm, GPhC 2232652, Superintendent Pharmacist, Solira.